Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The company’s focus is on those disorders that are associated with a steroid hormone called cortisol. The company has been developing mifepristone — a potent glucocorticoid receptor II (GR-II) antagonist that blocks the activity of cortisol — for the treatment of severe metabolic and psychiatric disorders. The company has also discovered three series of novel selective GR-II antagonists and has moved a compound from one of these series into clinical development. Operations Cushing’s Syndrome: In 2012, the United States Food and Drug Administration (FDA) approved Korlym (mifepristone) 300 mg Tablets as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company made Korlym available to patients in April 2012. The company markets Korlym in the United States. Psychotic Depression: The company also has an on-going Phase 3 study of mifepristone, the active ingredient in Korlym, for the psychotic features of psychotic depression under a patent license from Stanford University. It is developing mifepristone as an oral medication to treat the psychotic features of psychotic depression. The company’s ongoing Phase 3 clinical trial, Study 14, evaluating mifepristone for the treatment of the psychotic features of psychotic depression is being conducted under an agreement with ICON Clinical Research, LP. In addition, the company entered into an agreement with MedAvante, Inc. to provide the centralized psychiatric diagnosis and rating services for patients being screened and enrolled in Study 14. Next-Generation Selective GR-II Antagonists for the Prevention and Reversal of Antipsychotic-Induced Weight Gain: The company announced results from two preclinical studies of its first next-generation selective GR-II receptor antagonist, CORT 108297, for the prevention and reversal of weight gain caused by olanzapine. CORT 108297 is in exploratory Phase 2 clinical trials and the company plans to explore its potential use in various indications. Research and Development The company incurred approximately $14.1 million in the year ended December 31, 2012. Intellectual Property The company’s registered trademarks include Corcept and CORLUX. A trademark is pending with respect to Korlym. It also owns issued U.S. patents for the use of GR-II antagonists in the treatment of mild cognitive impairment, for the treatment of weight gain following treatment with antipsychotic medication, for the prevention and treatment of stress disorders, for increasing the therapeutic response to electroconvulsive therapy, for the treatment of delirium, for the treatment of catatonia, for the treatment of gastroesophageal reflux disease and for inhibiting cognitive deterioration in adults with Down’s Syndrome. The expiration dates of these patents and their foreign counterparts range from 2020 to 2028. History Corcept Therapeutics Incorporated was founded in 1998. The company was incorporated in the state of Delaware in 1998.
corcept therapeutics inc
149 Commonwealth Drive
Menlo Park, CA 94025
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.